Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.

Employees - 9, CEO - James Frakes, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -41.48, Piotroski Score(max is 10): 2, Working Capital: $4122702, Total Assets: $6333107, Retained Earnings: $-175106000, EBIT: -7196494, Total Liabilities: $1446835, Revenue: $0

- Current Price $ - Analyst Target Price $